Gene · 9436
Papers3,322
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,322
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. | J Gynecol Oncol | 2024 | 38606823 | PubTator, text mining | PubMed |
| A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis. | Blood Adv | 2024 | 38484189 | PubTator, text mining | PubMed |
| Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia. | Cancer Cell Int | 2024 | 38481242 | PubTator, text mining | PubMed |
| Angelica gigas polysaccharide induces CR3-mediated macrophage activation and the cytotoxicity of natural killer cells against HCT-116 cells via NF-κB and MAPK signaling pathways. | Int J Biol Macromol | 2024 | 38412933 | PubTator, text mining | PubMed |
| Natural Killer Cells as a Further Insight into the Course of Chronic Obstructive Pulmonary Disease. | Biomedicines | 2024 | 38398020 | PubTator, text mining | PubMed |
| Involvement of M1-Activated Macrophages and Perforin/Granulysin Expressing Lymphocytes in IgA Vasculitis Nephritis. | Int J Mol Sci | 2024 | 38396930 | PubTator, text mining | PubMed |
| Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo. | Cytotherapy | 2024 | 38363249 | PubTator, text mining | PubMed |
| Donor Age Correlates With Liver-Resident Natural Killer Cell Activity in Adoptive Immunotherapy Using Donor Liver Natural Killer Cells in Liver Transplantation. | Transplant Proc | 2024 | 38326202 | PubTator, text mining | PubMed |
| A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels. | Blood | 2024 | 38320121 | PubTator, text mining | PubMed |
| Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. | Discov Oncol | 2024 | 38294629 | PubTator, text mining | PubMed |
| VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. | Nat Commun | 2024 | 38291039 | PubTator, text mining | PubMed |
| Variation in the basal immune state and implications for disease. | Elife | 2024 | 38275224 | PubTator, text mining | PubMed |
| Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity. | Immun Inflamm Dis | 2024 | 38270321 | PubTator, text mining | PubMed |
| The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. | Cell Commun Signal | 2024 | 38254135 | PubTator, text mining | PubMed |
| A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. | J Immunol | 2024 | 38251887 | PubTator, text mining | PubMed |
| Breakthrough of solid tumor treatment: CAR-NK immunotherapy. | Cell Death Discov | 2024 | 38245520 | PubTator, text mining | PubMed |
| Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells. | Immunohorizons | 2024 | 38240638 | PubTator, text mining | PubMed |
| Harnessing natural killer cell effector function against cancer. | Immunother Adv | 2024 | 38223411 | PubTator, text mining | PubMed |
| Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. | Cell Death Dis | 2024 | 38221520 | PubTator, text mining | PubMed |
| Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications. | Virol J | 2024 | 38216935 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9436/papers?page=6